Antony A. Riley - Oct 1, 2024 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Stock symbol: FBRX
Transactions as of: Oct 1, 2024
Transactions value $: -$686
Form type: 4
Date filed: 10/2/2024, 06:21 PM
Previous filing: Jul 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FBRX	Common Stock	Options Exercise	$0	+375	+4.68%	$0.00	8.4K	Oct 1, 2024	Direct	F1, F2
transaction	FBRX	Common Stock	Tax liability	-$686	-133	-1.58%	$5.16	8.26K	Oct 1, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FBRX	Restricted Stock Units	Options Exercise	$0	-375	-10%	$0.00	3.38K	Oct 1, 2024	Common Stock	375		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
F2	The reported number of securities has been adjusted to reflect the Issuer's 1-for-25 reverse stock split effected on August 28, 2024.
F3	Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.